Should Antihypertensive Therapy Target Both LVH and BP?
On-treatment regression, or continued absence, of electrocardiographically assessed left-ventricular hypertrophy was associated with reduced risk for new-onset atrial fibrillation in the LIFE study.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)